MARKET

SYBX

SYBX

Synlogic
NASDAQ
1.910
-0.040
-2.05%
After Hours: 1.880 -0.03 -1.57% 18:04 02/23 EST
OPEN
1.860
PREV CLOSE
1.950
HIGH
1.962
LOW
1.790
VOLUME
56.84K
TURNOVER
0
52 WEEK HIGH
13.04
52 WEEK LOW
1.550
MARKET CAP
17.55M
P/E (TTM)
-0.1502
1D
5D
1M
3M
1Y
5Y
Synlogic Announces Top Executive Departures and Compensation Deals
TipRanks · 3d ago
Synlogic Enacts Shareholder Rights Plan for Equitable Control
TipRanks · 5d ago
Synlogic Adopts Limited Duration Stockholders Rights Plan And Authorized A Dividend Distribution Of One Right For Each Outstanding Share Of Common Stock; Effective Immediately And Has A 1-Year Duration, Expiring On February 20, 2025
Synlogic, Inc. Has approved the adoption of a limited duration shareholder rights plan. The Board also authorized a dividend distribution of one right for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025.
Benzinga · 5d ago
Weekly Report: what happened at SYBX last week (0212-0216)?
Weekly Report · 6d ago
Hold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price Target
Analyst Joseph Schwartz from Leerink Partners downgraded the rating on the stock to a Hold and gave it a $1.00 price target. Synlogic's lead program, SYNB1934, was in development for treating phenylketonuria. The Wall Street analyst's downgrade reflects a cautious outlook on the company's prospects.
TipRanks · 02/13 10:13
Synlogic Announces Major Restructuring and Leadership Changes
TipRanks · 02/12 21:14
Weekly Report: what happened at SYBX last week (0205-0209)?
Weekly Report · 02/12 12:08
Health Care Sector Update for 02/09/2024: SYBX, MRNA, ADAG, HUMA
NASDAQ · 02/09 20:54
More
About SYBX
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The Company uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. The Company also has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The Company has also developed two drug candidates through a research collaboration with Ginkgo Bioworks, Inc: SYNB1353, designed to consume methionine for the potential treatment of homocystinuria (HCU), and SYNB2081, designed to lower uric acid for the potential treatment of gout.

Webull offers Synlogic Inc stock information, including NASDAQ: SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.